ORLAAM
LOE Approachinglevomethadyl acetate hydrochloride
NDAORALCONCENTRATEPriority Review
Approved
Jul 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORLAAM (levomethadyl acetate hydrochloride) is an oral concentrate opioid agonist approved in 1993 for opioid use disorder maintenance treatment. It is a long-acting synthetic opioid that provides sustained therapeutic levels with less frequent dosing than methadone. The drug is administered as an oral liquid concentrate.
LOE Approaching
Product is in late-stage lifecycle with declining market opportunity; commercial teams should expect reduced headcount and focus on managed transition strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ORLAAM offers limited career growth opportunity given its LOE-approaching lifecycle and minimal linked job openings. This role is best suited for professionals with managed decline expertise or those seeking stability in a niche therapeutic area.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.